[
  {
    "ts": "2025-12-11T05:10:38+00:00",
    "headline": "Did Eli Lilly's (LLY) US$6 Billion Alabama Bet on Orforglipron Just Shift Its Investment Narrative?",
    "summary": "Eli Lilly and Company recently announced plans to invest more than US$6.00 billion in a new Huntsville, Alabama API facility that will produce small‑molecule and peptide medicines, including its oral GLP‑1 obesity candidate orforglipron, with construction slated to begin in 2026 and completion targeted for 2032. Alongside this large U.S. manufacturing build‑out, Lilly is advancing Jaypirca in leukemia with Phase 3 data and expanded FDA approval, underscoring how obesity and oncology...",
    "url": "https://finance.yahoo.com/news/did-eli-lillys-lly-us-051038418.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "280a4dfc-8c44-3217-a112-317e692ac122",
      "content": {
        "id": "280a4dfc-8c44-3217-a112-317e692ac122",
        "contentType": "STORY",
        "title": "Did Eli Lilly's (LLY) US$6 Billion Alabama Bet on Orforglipron Just Shift Its Investment Narrative?",
        "description": "",
        "summary": "Eli Lilly and Company recently announced plans to invest more than US$6.00 billion in a new Huntsville, Alabama API facility that will produce small‑molecule and peptide medicines, including its oral GLP‑1 obesity candidate orforglipron, with construction slated to begin in 2026 and completion targeted for 2032. Alongside this large U.S. manufacturing build‑out, Lilly is advancing Jaypirca in leukemia with Phase 3 data and expanded FDA approval, underscoring how obesity and oncology...",
        "pubDate": "2025-12-11T05:10:38Z",
        "displayTime": "2025-12-11T05:10:38Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uZWvuDuy6_Wr6cKvxAFZcw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g78F5NO5pySOmBHzFi6.eA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/did-eli-lillys-lly-us-051038418.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/did-eli-lillys-lly-us-051038418.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-11T07:00:00+00:00",
    "headline": "Microsoft, Broadcom, Lilly, and Other Stocks That Meet This Pro’s Definition of ‘Quality’",
    "summary": "Tom Hancock, a portfolio manager at GMO, favors companies that consistently earn a high return on capital and reinvest in the business.",
    "url": "https://www.barrons.com/articles/microsoft-broadcom-lilly-stocks-f036c3cc?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "2da8b293-1ab5-34e6-8cef-c1d728ca2038",
      "content": {
        "id": "2da8b293-1ab5-34e6-8cef-c1d728ca2038",
        "contentType": "STORY",
        "title": "Microsoft, Broadcom, Lilly, and Other Stocks That Meet This Pro’s Definition of ‘Quality’",
        "description": "",
        "summary": "Tom Hancock, a portfolio manager at GMO, favors companies that consistently earn a high return on capital and reinvest in the business.",
        "pubDate": "2025-12-11T07:00:00Z",
        "displayTime": "2025-12-11T07:00:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/2da8b293-1ab5-34e6-8cef-c1d728ca2038/microsoft-broadcom-lilly-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/343e152b8141ff37e2072d778b84cfd1",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Hy6O0hbzpqCmO0W7v8y2Rg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/343e152b8141ff37e2072d778b84cfd1.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hb0p.6Z7.pB7JoES9lq54Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/343e152b8141ff37e2072d778b84cfd1.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/microsoft-broadcom-lilly-stocks-f036c3cc?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MSFT"
            },
            {
              "symbol": "AVGO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-11T07:52:25+00:00",
    "headline": "Eli Lilly’s Mounjaro Added to China’s National Health Insurance for Diabetes",
    "summary": "Eli Lilly and Company (NYSE:LLY) is included among the 15 Best Stocks to Buy for the Long Term. Eli Lilly and Company (NYSE:LLY)’s popular drug Mounjaro will be added to China’s state-run health insurance program starting January 1, the National Healthcare Security Administration said in a notice on December 8. Analysts say that the move […]",
    "url": "https://finance.yahoo.com/news/eli-lilly-mounjaro-added-china-075225117.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "460f09e2-4a74-31cd-a6cd-2de0478c6595",
      "content": {
        "id": "460f09e2-4a74-31cd-a6cd-2de0478c6595",
        "contentType": "STORY",
        "title": "Eli Lilly’s Mounjaro Added to China’s National Health Insurance for Diabetes",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE:LLY) is included among the 15 Best Stocks to Buy for the Long Term. Eli Lilly and Company (NYSE:LLY)’s popular drug Mounjaro will be added to China’s state-run health insurance program starting January 1, the National Healthcare Security Administration said in a notice on December 8. Analysts say that the move […]",
        "pubDate": "2025-12-11T07:52:25Z",
        "displayTime": "2025-12-11T07:52:25Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Eli Lilly’s Mounjaro Added to China’s National Health Insurance for Diabetes",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6aY42asq7dEA24eM0JX3IQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8359URliL1_uJRGx4OlSUg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-mounjaro-added-china-075225117.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-mounjaro-added-china-075225117.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-11T06:15:00+00:00",
    "headline": "Novo Nordisk Is Trading as If Obesity Drug Craze Never Happened",
    "summary": "The slump has virtually wiped out several years of stellar gains that came after Novo’s Wegovy drug was approved as a weight-loss treatment in 2021.  “When I look at it right now, organically, their pipeline doesn’t convince me that this situation is manageable,” said Paul Major, a portfolio manager at Bellevue Asset Management.  Novo bulls are hoping that pending approvals of a higher-dose Wegovy shot and an oral version of the drug will turn things around and boost the company’s position against rival Eli Lilly & Co. Novo has sought approval of the stronger injectable version of Wegovy in the US under a priority voucher, which will speed review.",
    "url": "https://finance.yahoo.com/news/novo-nordisk-trading-obesity-drug-061500298.html",
    "source": "Bloomberg",
    "provider": "yfinance",
    "raw": {
      "id": "1ca66d58-8013-3e8b-8914-b38a062a9450",
      "content": {
        "id": "1ca66d58-8013-3e8b-8914-b38a062a9450",
        "contentType": "STORY",
        "title": "Novo Nordisk Is Trading as If Obesity Drug Craze Never Happened",
        "description": "",
        "summary": "The slump has virtually wiped out several years of stellar gains that came after Novo’s Wegovy drug was approved as a weight-loss treatment in 2021.  “When I look at it right now, organically, their pipeline doesn’t convince me that this situation is manageable,” said Paul Major, a portfolio manager at Bellevue Asset Management.  Novo bulls are hoping that pending approvals of a higher-dose Wegovy shot and an oral version of the drug will turn things around and boost the company’s position against rival Eli Lilly & Co. Novo has sought approval of the stronger injectable version of Wegovy in the US under a priority voucher, which will speed review.",
        "pubDate": "2025-12-11T06:15:00Z",
        "displayTime": "2025-12-11T06:15:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2025-12/03d1cb40-d66f-11f0-bdfb-ee6487c841eb",
          "originalWidth": 5086,
          "originalHeight": 3391,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aZoqsZiNz1K4FmBk81kNFg--~B/aD0zMzkxO3c9NTA4NjthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2025-12/03d1cb40-d66f-11f0-bdfb-ee6487c841eb.cf.webp",
              "width": 5086,
              "height": 3391,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LuK9B6s8jPY9CaBFC6_eYA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2025-12/03d1cb40-d66f-11f0-bdfb-ee6487c841eb.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Bloomberg",
          "url": "https://www.bloomberg.com/company"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-trading-obesity-drug-061500298.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-trading-obesity-drug-061500298.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "ZLDPF"
            },
            {
              "symbol": "HIMS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-11T12:40:57+00:00",
    "headline": "Dow Jones Futures Rise, Techs Pare Losses; Oracle Dives On AI Spending",
    "summary": "Futures reversed higher and techs pared losses though Oracle dived on AI spending fears. GE Vernova, Palantir made bullish moves Wednesday in a Fed-led rally.",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-fed-chief-powell-ge-vernova-palantir-oracle-earnings/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "932fb9b7-9b2b-3f29-831f-b970e231b81c",
      "content": {
        "id": "932fb9b7-9b2b-3f29-831f-b970e231b81c",
        "contentType": "STORY",
        "title": "Dow Jones Futures Rise, Techs Pare Losses; Oracle Dives On AI Spending",
        "description": "",
        "summary": "Futures reversed higher and techs pared losses though Oracle dived on AI spending fears. GE Vernova, Palantir made bullish moves Wednesday in a Fed-led rally.",
        "pubDate": "2025-12-11T12:40:57Z",
        "displayTime": "2025-12-11T12:40:57Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/932fb9b7-9b2b-3f29-831f-b970e231b81c/dow-jones-futures-rise-techs.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/08ab03dd3e698a6cda00ec304163410f",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/GpkKDCUrNg1ja0_lqlSK1A--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/08ab03dd3e698a6cda00ec304163410f.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LAjcPgxzP9O6nq7I4ejKrg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/08ab03dd3e698a6cda00ec304163410f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-fed-chief-powell-ge-vernova-palantir-oracle-earnings/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ORCL"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "CIEN"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "GEV"
            },
            {
              "symbol": "TSLA"
            },
            {
              "symbol": "PLTR"
            },
            {
              "symbol": "VRT"
            },
            {
              "symbol": "TSM"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-11T12:38:00+00:00",
    "headline": "Eli Lilly's Experimental Obesity Drug Cut Weight By 23.7%",
    "summary": "Eli Lily rose above a key level after saying its experimental obesity treatment delivered 23.7% weight loss in a late-stage trial.",
    "url": "https://www.investors.com/news/technology/eli-lillys-experimental-obesity-drug-cut-weight-by-23-7/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "54f21ac2-42c3-374f-b93b-7ca50b9e44ba",
      "content": {
        "id": "54f21ac2-42c3-374f-b93b-7ca50b9e44ba",
        "contentType": "STORY",
        "title": "Eli Lilly's Experimental Obesity Drug Cut Weight By 23.7%",
        "description": "",
        "summary": "Eli Lily rose above a key level after saying its experimental obesity treatment delivered 23.7% weight loss in a late-stage trial.",
        "pubDate": "2025-12-11T12:38:00Z",
        "displayTime": "2025-12-11T12:38:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/54f21ac2-42c3-374f-b93b-7ca50b9e44ba/eli-lilly-s-experimental.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/6cd90493ab72db2581488636ff69862e",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/10YtRIZ9HivbFYhXLR9gBA--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/6cd90493ab72db2581488636ff69862e.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bFPz_0vx1nYfB7PzzhdAEA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/6cd90493ab72db2581488636ff69862e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/eli-lillys-experimental-obesity-drug-cut-weight-by-23-7/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "VKTX"
            },
            {
              "symbol": "WVE"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "GPCR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-11T12:28:33+00:00",
    "headline": "Eli Lilly stock climbs after retatrutide delivers massive weight loss in trial",
    "summary": "Investing.com -- Eli Lilly (NYSE:LLY) stock rose 3% in premarket trading Thursday after the company’s experimental triple agonist drug retatrutide showed impressive weight loss results and significant osteoarthritis pain relief in its first successful Phase 3 trial.",
    "url": "https://finance.yahoo.com/news/eli-lilly-stock-climbs-retatrutide-122833611.html",
    "source": "Investing.com",
    "provider": "yfinance",
    "raw": {
      "id": "e36ba9d1-0627-3c26-890b-16f4fa05873a",
      "content": {
        "id": "e36ba9d1-0627-3c26-890b-16f4fa05873a",
        "contentType": "STORY",
        "title": "Eli Lilly stock climbs after retatrutide delivers massive weight loss in trial",
        "description": "",
        "summary": "Investing.com -- Eli Lilly (NYSE:LLY) stock rose 3% in premarket trading Thursday after the company’s experimental triple agonist drug retatrutide showed impressive weight loss results and significant osteoarthritis pain relief in its first successful Phase 3 trial.",
        "pubDate": "2025-12-11T12:28:33Z",
        "displayTime": "2025-12-11T12:28:33Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Investing.com",
          "url": "https://www.investing.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-stock-climbs-retatrutide-122833611.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-stock-climbs-retatrutide-122833611.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-11T11:45:00+00:00",
    "headline": "Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 TRIUMPH-4 clinical trial evaluating the safety and efficacy of the two highest investigational doses of retatrutide, a first-in-class GIP, GLP-1 and glucagon triple hormone receptor agonist, in adults with obesity or overweight and knee osteoarthritis, and without diabetes, as an adjunct to healthy diet and physical activity. In this global registration trial, where 84.0% of participants had a baseline BM",
    "url": "https://finance.yahoo.com/news/lillys-triple-agonist-retatrutide-delivered-114500351.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "55439907-b6d6-37fb-ae24-1e5fece310c9",
      "content": {
        "id": "55439907-b6d6-37fb-ae24-1e5fece310c9",
        "contentType": "STORY",
        "title": "Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 TRIUMPH-4 clinical trial evaluating the safety and efficacy of the two highest investigational doses of retatrutide, a first-in-class GIP, GLP-1 and glucagon triple hormone receptor agonist, in adults with obesity or overweight and knee osteoarthritis, and without diabetes, as an adjunct to healthy diet and physical activity. In this global registration trial, where 84.0% of participants had a baseline BM",
        "pubDate": "2025-12-11T11:45:00Z",
        "displayTime": "2025-12-11T11:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee",
          "originalWidth": 400,
          "originalHeight": 219,
          "caption": "Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7Y1fhfHoGbpYMTG8q90VAg--~B/aD0yMTk7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 400,
              "height": 219,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.Goic7S8PJ1_UseTWpNhHw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lillys-triple-agonist-retatrutide-delivered-114500351.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lillys-triple-agonist-retatrutide-delivered-114500351.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-11T13:33:00+00:00",
    "headline": "Lilly Reports Positive Results in Next-Gen Obesity Drug Trial",
    "summary": "Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in a late-stage trial.",
    "url": "https://www.wsj.com/health/pharma/eli-lilly-reports-positive-results-from-study-of-weight-loss-drug-c4cc3af7",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "1bf760c1-c435-353d-a930-0b9e76c09734",
      "content": {
        "id": "1bf760c1-c435-353d-a930-0b9e76c09734",
        "contentType": "STORY",
        "title": "Lilly Reports Positive Results in Next-Gen Obesity Drug Trial",
        "description": "",
        "summary": "Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in a late-stage trial.",
        "pubDate": "2025-12-11T13:33:00Z",
        "displayTime": "2025-12-11T13:33:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/the_wall_street_journal_hosted_996/f5c9d70a99f3ffa69ebadd5212a03fdf",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dVjT1MIwif5CWgTNyE1exg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/the_wall_street_journal_hosted_996/f5c9d70a99f3ffa69ebadd5212a03fdf.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hYdYCCjGLf0H07JsNglB2A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/the_wall_street_journal_hosted_996/f5c9d70a99f3ffa69ebadd5212a03fdf.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/eli-lilly-reports-positive-results-from-study-of-weight-loss-drug-c4cc3af7",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-reports-positive-results-125400633.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-11T13:00:00+00:00",
    "headline": "Crux Adds Obesity Management Medicine to its Newly Launched Employer Benefit Platform",
    "summary": "MCLEAN, Va., December 11, 2025--Crux, the first no-fee benefits platform working directly with pharmaceutical companies and employers of all sizes to expand transparent and affordable access to transformative FDA-approved medications, today announced Eli Lilly and Company’s Zepbound® will be the first medication available on its platform.",
    "url": "https://finance.yahoo.com/news/crux-adds-obesity-management-medicine-130000526.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "ae32291e-d3e2-3999-bd95-ac0b687fb881",
      "content": {
        "id": "ae32291e-d3e2-3999-bd95-ac0b687fb881",
        "contentType": "STORY",
        "title": "Crux Adds Obesity Management Medicine to its Newly Launched Employer Benefit Platform",
        "description": "",
        "summary": "MCLEAN, Va., December 11, 2025--Crux, the first no-fee benefits platform working directly with pharmaceutical companies and employers of all sizes to expand transparent and affordable access to transformative FDA-approved medications, today announced Eli Lilly and Company’s Zepbound® will be the first medication available on its platform.",
        "pubDate": "2025-12-11T13:00:00Z",
        "displayTime": "2025-12-11T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/eea508e52f649c33bf55c18dc2fd8ddf",
          "originalWidth": 2481,
          "originalHeight": 639,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/gpV3iK43cmOWWaFW2VCTlQ--~B/aD02Mzk7dz0yNDgxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/eea508e52f649c33bf55c18dc2fd8ddf.cf.webp",
              "width": 2481,
              "height": 639,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BaoiVrs0FWu8xwcubNYjnw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/eea508e52f649c33bf55c18dc2fd8ddf.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/crux-adds-obesity-management-medicine-130000526.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/crux-adds-obesity-management-medicine-130000526.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-11T12:54:00+00:00",
    "headline": "Eli Lilly Reports Positive Results From Study of Weight Loss Drug",
    "summary": "Eli Lilly’s experimental weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in a phase three trial involving patients with obesity and knee osteoarthritis.",
    "url": "https://www.wsj.com/health/pharma/eli-lilly-reports-positive-results-from-study-of-weight-loss-drug-c4cc3af7?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "675bcc3c-b3a3-3400-88a3-98d9806c0474",
      "content": {
        "id": "675bcc3c-b3a3-3400-88a3-98d9806c0474",
        "contentType": "STORY",
        "title": "Eli Lilly Reports Positive Results From Study of Weight Loss Drug",
        "description": "",
        "summary": "Eli Lilly’s experimental weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in a phase three trial involving patients with obesity and knee osteoarthritis.",
        "pubDate": "2025-12-11T12:54:00Z",
        "displayTime": "2025-12-11T12:54:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/675bcc3c-b3a3-3400-88a3-98d9806c0474/eli-lilly-reports-positive.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/f5c9d70a99f3ffa69ebadd5212a03fdf",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5S_vNkgaTAXYa.ludgCo8Q--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/f5c9d70a99f3ffa69ebadd5212a03fdf.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0GnFyWx.S.4TdR0JjC3pUQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/f5c9d70a99f3ffa69ebadd5212a03fdf.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/eli-lilly-reports-positive-results-from-study-of-weight-loss-drug-c4cc3af7?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-11T07:00:00+00:00",
    "headline": "Prolynx banks $70M for longer-lasting obesity drugs",
    "summary": "Using a kind of novel linker technology, the startup is developing versions of incretin and non-incretin therapies that can be administered monthly or quarterly.",
    "url": "https://www.biopharmadive.com/news/prolynx-obesity-drugs-biotech-startup-series-a/807611/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "88215df6-7bd0-3980-9412-dc62f268bd11",
      "content": {
        "id": "88215df6-7bd0-3980-9412-dc62f268bd11",
        "contentType": "STORY",
        "title": "Prolynx banks $70M for longer-lasting obesity drugs",
        "description": "",
        "summary": "Using a kind of novel linker technology, the startup is developing versions of incretin and non-incretin therapies that can be administered monthly or quarterly.",
        "pubDate": "2025-12-11T07:00:00Z",
        "displayTime": "2025-12-11T07:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/de455cf977ae72652b6b290fa7d338b8",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "An assortment of weight loss and diabetic drugs sit on a table in New South Wales, Australia, in May 2024.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sG6vGRz6Poy.6e9_k4nVlw--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/de455cf977ae72652b6b290fa7d338b8.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iw0g99hXu_nDi5Z8YBBthg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/de455cf977ae72652b6b290fa7d338b8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/prolynx-obesity-drugs-biotech-startup-series-a/807611/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/prolynx-banks-70m-longer-lasting-070000175.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-11T14:32:31+00:00",
    "headline": "Eli Lilly's obesity drug trial results, Coca-Cola names next CEO",
    "summary": "Morning Brief host Julie Hyman tracks several of the day's top trending stock tickers, including the results of Eli Lilly's (LLY) latest obesity drug test, Coca-Cola (KO) named Henrique Braun as the next CEO after current chief executive James Quincey steps down from the role at the end of March 2026, and Gemini Space Station (GEMI) receiving approval to operate as a predictions market by the Commodity Futures Trading Commission (CFTC). To watch more expert insights and analysis on the latest market action, check out more&nbsp;Morning Brief.",
    "url": "https://finance.yahoo.com/video/eli-lillys-obesity-drug-trial-143231235.html",
    "source": "Yahoo Finance Video",
    "provider": "yfinance",
    "raw": {
      "id": "96875aaf-2aca-3a92-bfef-639992e49a53",
      "content": {
        "id": "96875aaf-2aca-3a92-bfef-639992e49a53",
        "contentType": "VIDEO",
        "title": "Eli Lilly's obesity drug trial results, Coca-Cola names next CEO",
        "description": "<p>Morning Brief host <a data-i13n=\"cpos:1;pos:1\" href=\"https://www.yahoo.com/author/julie-hyman/?.tsrc=fin-srch\">Julie Hyman</a> tracks several of the day's top trending stock tickers, including the results of Eli Lilly's (<a data-i13n=\"cpos:2;pos:1\" href=\"https://finance.yahoo.com/quote/LLY\">LLY</a>) latest obesity drug test, Coca-Cola (<a data-i13n=\"cpos:3;pos:1\" href=\"https://finance.yahoo.com/quote/KO\">KO</a>) named Henrique Braun as the next CEO after current chief executive James Quincey steps down from the role at the end of March 2026, and Gemini Space Station (<a data-i13n=\"cpos:4;pos:1\" href=\"https://finance.yahoo.com/quote/GEMI\">GEMI</a>) receiving approval to operate as a predictions market by the Commodity Futures Trading Commission (CFTC).</p>\n<p>To watch more expert insights and analysis on the latest market action, check out more <a data-i13n=\"cpos:5;pos:1\" href=\"https://finance.yahoo.com/videos/series/morning-brief/\">Morning Brief</a>.</p>",
        "summary": "Morning Brief host Julie Hyman tracks several of the day's top trending stock tickers, including the results of Eli Lilly's (LLY) latest obesity drug test, Coca-Cola (KO) named Henrique Braun as the next CEO after current chief executive James Quincey steps down from the role at the end of March 2026, and Gemini Space Station (GEMI) receiving approval to operate as a predictions market by the Commodity Futures Trading Commission (CFTC). To watch more expert insights and analysis on the latest market action, check out more&nbsp;Morning Brief.",
        "pubDate": "2025-12-11T14:32:31Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2025-12/326a00b0-d69e-11f0-b6da-7eea42405096",
          "originalWidth": 2874,
          "originalHeight": 1618,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wWoNr4ybF7vOJPFLTMc_Iw--~B/aD0xNjE4O3c9Mjg3NDthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2025-12/326a00b0-d69e-11f0-b6da-7eea42405096.cf.webp",
              "width": 2874,
              "height": 1618,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/grB0CgPOfcZVBmcJti52QA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2025-12/326a00b0-d69e-11f0-b6da-7eea42405096.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance Video",
          "url": "https://finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/eli-lillys-obesity-drug-trial-143231235.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/eli-lillys-obesity-drug-trial-143231235.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": true
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "GEMI"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-11T14:35:42+00:00",
    "headline": "New Lilly Shot Reduces Body Weight by 23% in Study",
    "summary": "A next-generation obesity shot from Eli Lilly helped patients lose nearly a quarter of their body weight, potentially making the experimental drug the most potent weight-loss medicine yet. Madison Muller reports on Bloomberg Television.",
    "url": "https://finance.yahoo.com/video/lilly-shot-reduces-body-weight-143542397.html",
    "source": "Bloomberg",
    "provider": "yfinance",
    "raw": {
      "id": "5707cc23-f036-3510-adad-9e9662d8d355",
      "content": {
        "id": "5707cc23-f036-3510-adad-9e9662d8d355",
        "contentType": "VIDEO",
        "title": "New Lilly Shot Reduces Body Weight by 23% in Study",
        "description": "A next-generation obesity shot from Eli Lilly helped patients lose nearly a quarter of their body weight, potentially making the experimental drug the most potent weight-loss medicine yet. Madison Muller reports on Bloomberg Television.",
        "summary": "A next-generation obesity shot from Eli Lilly helped patients lose nearly a quarter of their body weight, potentially making the experimental drug the most potent weight-loss medicine yet. Madison Muller reports on Bloomberg Television.",
        "pubDate": "2025-12-11T14:35:42Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/bloomberg_markets_video_2/f75ec2a7a34906e7d00e490647925a00",
          "originalWidth": 1280,
          "originalHeight": 720,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jRueqdT7d6hSot77NgVeLQ--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/bloomberg_markets_video_2/f75ec2a7a34906e7d00e490647925a00.cf.webp",
              "width": 1280,
              "height": 720,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/myUZQvlYVeEOV1sPRXQgHg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/bloomberg_markets_video_2/f75ec2a7a34906e7d00e490647925a00.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Bloomberg",
          "url": "https://www.bloomberg.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/lilly-shot-reduces-body-weight-143542397.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/lilly-shot-reduces-body-weight-143542397.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-11T14:30:00+00:00",
    "headline": "Eli Lilly Reports Dramatic Weight Loss in Next-Gen Obesity-Drug Trial",
    "summary": "Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in a late-stage trial.",
    "url": "https://www.wsj.com/health/pharma/eli-lilly-reports-positive-results-from-study-of-weight-loss-drug-c4cc3af7?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "675bcc3c-b3a3-3400-88a3-98d9806c0474",
      "content": {
        "id": "675bcc3c-b3a3-3400-88a3-98d9806c0474",
        "contentType": "STORY",
        "title": "Eli Lilly Reports Dramatic Weight Loss in Next-Gen Obesity-Drug Trial",
        "description": "",
        "summary": "Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in a late-stage trial.",
        "pubDate": "2025-12-11T14:30:00Z",
        "displayTime": "2025-12-11T14:30:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/675bcc3c-b3a3-3400-88a3-98d9806c0474/eli-lilly-reports-dramatic.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/d6aab201a6cdbd93822b65d068a09e65",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fgZ.4C7GYPDMmhmiDd8t5g--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/d6aab201a6cdbd93822b65d068a09e65.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HD4TJ2coTeN.TrPtvHrTmg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/d6aab201a6cdbd93822b65d068a09e65.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/eli-lilly-reports-positive-results-from-study-of-weight-loss-drug-c4cc3af7?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-11T14:26:08+00:00",
    "headline": "Eli Lilly Reports Strong Late-Stage Results for Next-Generation Obesity Drug Retatrutide",
    "summary": "This article first appeared on GuruFocus.  Eli Lilly (LLY, Financials) reported late-stage results showing its next-generation obesity drug retatrutide produced the strongest weight loss seen so far in a phase-three trial and reduced knee pain in patients with obesity and osteoarthritis.  The highest dose led to 23.7% average weight loss at 68 weeks when including all participants and 28.7% among those who completed treatment.",
    "url": "https://finance.yahoo.com/news/eli-lilly-reports-strong-stage-142608772.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "7ced9cfb-ed75-3b67-b19a-a525c50f70a9",
      "content": {
        "id": "7ced9cfb-ed75-3b67-b19a-a525c50f70a9",
        "contentType": "STORY",
        "title": "Eli Lilly Reports Strong Late-Stage Results for Next-Generation Obesity Drug Retatrutide",
        "description": "",
        "summary": "This article first appeared on GuruFocus.  Eli Lilly (LLY, Financials) reported late-stage results showing its next-generation obesity drug retatrutide produced the strongest weight loss seen so far in a phase-three trial and reduced knee pain in patients with obesity and osteoarthritis.  The highest dose led to 23.7% average weight loss at 68 weeks when including all participants and 28.7% among those who completed treatment.",
        "pubDate": "2025-12-11T14:26:08Z",
        "displayTime": "2025-12-11T14:26:08Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/434a82c75d97e3a5a22898838638d64c",
          "originalWidth": 6382,
          "originalHeight": 4786,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Klfzvp39.soPeoaiqKcS3w--~B/aD00Nzg2O3c9NjM4MjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/us.finance.gurufocus/434a82c75d97e3a5a22898838638d64c.cf.webp",
              "width": 6382,
              "height": 4786,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/W9CEpukOrGiNcDXN4UIi7Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/434a82c75d97e3a5a22898838638d64c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-reports-strong-stage-142608772.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-reports-strong-stage-142608772.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]